Your B-Vitamins Have a THTR Transporter Saturation Ceiling: Thiamine HCl Absorption Is Sharply Limited Regardless of Dose, and the Pharmacokinetic Data Has Been on PubMed Since 2014

Here’s the number that should reframe how you think about B1. Xie et al. (2014, Journal of Clinical Pharmacology, PMID: 24399744) measured roughly 1,147% relative plasma thiamine bioavailability, about 11-fold, and 196% relative erythrocyte TDP, about 2-fold, with benfotiamine versus thiamine HCl in a direct blood-level comparison. What makes it more than a diabetes footnote: Hammes et al. (2003) demonstrated the underlying mechanism in hyperglycemic and diabetic models, and because F6P and G3P are produced by ordinary glycolysis at any glucose level, the biochemistry suggests broader relevance. That broader relevance in metabolically healthy people is a reasoned inference from the mechanism, not something those studies directly tested.*

That’s the case for BioActive Vitamin B1™, Triquetra’s benfotiamine complete cofactor system built for metabolic performance support: 600mg fat-soluble benfotiamine with markedly higher plasma thiamine delivery than thiamine HCl (Xie et al. 2014), chelated magnesium for thiamine pyrophosphokinase activation, active P5P that helps bypass ALPL-associated conversion variability, and pharmaceutical-grade ALA at the dose validated in the ISLAND vascular study. It’s the bioavailability engineering and clinically-studied dose that commodity B-vitamins were never designed to provide.*

The problem with most B-vitamin protocols isn’t the dose. It’s the mechanism. THTR-1 (SLC19A2) is a sodium-dependent thiamine carrier with a Km around 2 to 2.5µM, so it saturates at low substrate concentrations. (THTR-2, SLC19A3, has a much lower, nanomolar-range Km in intestinal brush-border reports, meaning tighter affinity and still-limited flux at higher loads.) Pile more thiamine HCl onto a THTR-1 route that’s already near-saturated and you don’t get much more erythrocyte TDP. You mostly get more thiamine in your urine. This is Michaelis-Menten kinetics applied to a formulation decision, and the industry has mostly ignored it for decades.

Benfotiamine sidesteps the bottleneck by design. Its S-benzoylthiamine-O-monophosphate structure is lipophilic, so it diffuses passively through enterocyte lipid bilayers instead of waiting in line for a saturable carrier. Once inside, intracellular esterases cleave the S-benzoyl group, freeing thiamine for phosphorylation to thiamine pyrophosphate (TPP) via thiamine pyrophosphokinase (TPK). That’s where the plasma AUC difference and the higher erythrocyte TDP come from, and Xie et al. (2014) measured both from actual blood samples.

You’ve seen this logic before. If you already take methylfolate over folic acid and methylcobalamin over cyanocobalamin, you’ve run this exact reasoning on folate and B12. The same bioavailability argument holds for thiamine and B6. It just gets far less attention.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BioActive Vitamin B1: A Bioavailability-Engineered Complete Cofactor System for Metabolic Performance and Healthy AGE-Related Pathways

A note on the evidence before we go deeper: the human trials cited on this page were conducted in clinical populations, including diabetic neuropathy, type 1 diabetes, metabolic syndrome, and mild cognitive impairment. For metabolically healthy adults, the case here is mechanistic rationale supported by those disease-population RCTs, rather than outcomes confirmed by trials in healthy people. Where a study result is described, it reflects what that study found in its own population. Individual results may vary.

BioActive Vitamin B1™ , this benfotiamine complete cofactor system, supports the thiamine pyrophosphate (TPP) supply that mitochondrial enzymes depend on at pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transketolase. It provides 600mg benfotiamine via lipophilic passive diffusion that reduces reliance on THTR-1 saturation, activates transketolase to help redirect glycolytic flux away from methylglyoxal and AGE-precursor formation (Hammes et al. 2003, Nature Medicine), and combines chelated magnesium for TPP synthesis, active P5P for neurotransmitter cofactor completeness, and ALA for Nrf2 pathway support and AMPK-mediated GLUT4 translocation. Four complementary mechanisms, one GMP-certified formula.*

BioActive Vitamin B1 is a benfotiamine supplement manufactured in a GMP-certified, FDA-registered facility for metabolic performance support, healthy AGE-related pathways, and mitochondrial ATP flux support, made by Triquetra Health.* The target user is specific: quantified self practitioners and biohackers ages 25 to 50 with normal glucose metabolism who run CGM, HRV tracking, or full biomarker panels; already on methylfolate, methylcobalamin, and other active forms; and looking to help address the thiamine and B6 bioavailability gap in their protocol while supporting healthy AGE-related pathways from normal glycolytic flux.

The core of it is the cofactor system working as a unit: 600mg S-benzoylthiamine-O-monophosphate via lipophilic passive diffusion that reduces THTR-1 dependence (Xie 2014: ~1,147% relative plasma thiamine bioavailability, ~196% relative erythrocyte TDP); 200mg magnesium bis-glycinate as the obligate Mg²⁺ cofactor for thiamine pyrophosphokinase (TPK); 30mg P5P active coenzyme that helps sidestep ALPL-associated conversion variability; and 300mg racemic ALA supporting Nrf2 activation, AMPK-GLUT4 translocation, PDH/αKGD cofactor function, and the benfotiamine-plus-ALA approach studied by Du 2008.*

Six independent evidence sources sit behind it: Xie et al. 2014 (PMID: 24399744) for the PK quantification; Stracke et al. 2008 BENDIP Phase III (PMID: 18473286), per-protocol between-group significance p=0.033, n=165, with the 600mg arm showing the greatest symptom improvement; Hammes et al. 2003 (Nature Medicine, PMID: 12592403), transketolase activation and blockade of three glucose-damage pathways plus NF-κB, in hyperglycemic models; Du et al. 2008 (Diabetologia, PMID: 18663426), normalized elevated AGE formation independent of glycemic control in type 1 diabetics (benfotiamine 600mg + ALA 1200mg); Sola et al. 2005 ISLAND (Circulation, PMID: 15655130), 44% FMD improvement with 300mg ALA in metabolic syndrome; and Fraser et al. 2012 (Diabetes Care, PMID: 22446172), a significant whole-blood thiamine/TDP increase at p<0.001.

Manufacturing checks the boxes serious buyers ask about: GMP-certified per 21 CFR Part 111, NSF/USP-approved third-party lot testing, heavy metals screened per Prop 65, allergen-free, soy-free, gluten-free, dairy-free, non-GMO, vegetarian HPMC capsules, and Fullscript practitioner dispensary availability. BioActive Vitamin B1™ pairs a 600mg benfotiamine dose, matching the highest BENDIP arm, with active P5P, chelated Mg, and pharmaceutical-grade ALA in a single GMP-certified product with CoA transparency.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Full pharmacological specifications ↓

The Gap Your Active-Form Protocol May Have

If you’ve landed on this page, you’re not a typical supplement buyer. You’ve done the MTHFR research. You know why cyanocobalamin is a poor choice for B12, and why folic acid doesn’t stand in for methylfolate when hepatic MTHFR conversion is impaired. You have a take on whether R-ALA earns its price premium. You have opinions about which magnesium form actually survives the gut. You know what a CoA is, and you want to see one before you buy.

So here’s the odd part. Plenty of protocols exactly like yours still run thiamine HCl and pyridoxine HCl. Usually not because someone examined the question and judged those forms adequate, but because the active-form logic that companies applied to B12 and folate just stopped there. A lot of premium B-complexes use methylcobalamin and methylfolate, then quietly keep thiamine HCl and pyridoxine HCl for everything else. Most buyers never notice the inconsistency.

You’ve already shown you’ll act on bioavailability evidence. You made the methylfolate switch, and you understand the DHFR/MTHFR conversion step produces real functional differences in plasma PLP and cellular cofactor availability. The same kind of pharmacokinetic argument applies to thiamine and B6. The THTR saturation case for benfotiamine mirrors the MTHFR case for methylfolate, and the ALPL case for P5P mirrors the MTR/MTRR case for methylcobalamin. This isn’t new data, either. It’s been on PubMed since 2014.

None of this is hand-waving. The commodity thiamine HCl saturation ceiling is published and peer-reviewed. Whether benfotiamine at 150 to 300mg sits below the dose used in the highest BENDIP arm is a straightforward dose-response question, and BENDIP looked at it in 165 patients. Common ALPL variation influencing pyridoxine-to-PLP status shows up at genome-wide significance (p = 7.89 × 10⁻¹⁰). This formula applies the same bioavailability engineering you already demand from methylfolate and methylcobalamin, to every ingredient.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Why Standard Approaches Leave the TPP Supply and AGE-Related Pathways Unaddressed

The three approaches most Biohacker Optimizers have already tried each fall short in a specific, mechanistically defined way. Not general inadequacy. Targeted gaps.

Start with premium B-complex formulas built on methylcobalamin and methylfolate. They usually keep thiamine hydrochloride and pyridoxine HCl for the rest of the B-vitamins, which is the inconsistency: the same principle that justifies the methylcobalamin and methylfolate upgrade applies just as cleanly to thiamine and B6. A premium label doesn’t fix the THTR-1 saturation ceiling that holds thiamine HCl to a low absorbed fraction (active transport is saturable, so the fraction absorbed from a large oral dose is limited), and it doesn’t change the fact that common ALPL variation influences pyridoxine-to-PLP status regardless of brand. This formula extends the active B-vitamin stack the whole way: benfotiamine’s lipophilic passive diffusion for thiamine delivery (markedly higher plasma thiamine, Xie 2014), active P5P’s direct coenzyme provision for B6, chelated magnesium for TPP synthesis, and ALA for the vascular endpoint validated in ISLAND.*

Then there’s building the benfotiamine, P5P, magnesium, and ALA stack from separate bottles, the route a lot of research-literate people default to. It solves ingredient quality but creates fragmentation: four supply chains, four QC standards, four lot-testing regimes (most with none at all), and no one validating dose coordination across manufacturers. Worth noting on the evidence side, the Du 2008 proof-of-concept paired benfotiamine with ALA at a higher ALA dose (1200mg) than most single-bottle stacks carry. This formula delivers all four components, 600mg benfotiamine, 30mg P5P, 200mg chelated Mg, 300mg ALA, made together under single GMP-certified standards with NSF/USP-approved third-party lot testing, CoA documentation, and Fullscript availability. Consolidation also drops the typical monthly cost to $40 to $45, versus $100+ for the same components sourced separately (a comparison based on average retail prices of standalone benfotiamine, P5P, magnesium bis-glycinate, and ALA supplements as of [month/year]; individual pricing varies by brand and retailer).

Then the longevity heavyweights: NMN/NR, resveratrol, rapamycin. These run on different tracks from what benfotiamine targets. NMN works through sirtuin and PARP pathways via NAD+, resveratrol activates SIRT1, mTOR inhibition addresses autophagy and senescence. None of them touch THTR saturation, the methylglyoxal flux that benfotiamine’s transketolase activation helps divert, or the ALPL-associated conversion question. So this isn’t an alternative to your NAD+ or mTOR protocol. It’s the complementary layer those interventions leave open.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The Six-Stage Mechanistic Cascade: From THTR Bypass to Transketolase Support and Nrf2 Activation

Here’s how the cascade actually runs, stage by stage: 600mg benfotiamine via lipophilic passive diffusion that reduces reliance on THTR-1 saturation, transketolase activation that helps redirect glycolytic flux away from methylglyoxal and AGE-precursor formation (Hammes et al. 2003), plus chelated magnesium, active P5P, and ALA covering four complementary mechanisms.*

Stage 1: Lipophilic Passive Diffusion Reducing THTR Transporter Dependence

Thiamine HCl absorption runs through THTR-1 (SLC19A2), a sodium-dependent carrier with a Km around 2 to 2.5µM. (THTR-2, SLC19A3, sits on the luminal brush border with a much lower, nanomolar-range Km in several reports, so it’s higher-affinity but still a finite, carrier-mediated route.) Under Michaelis-Menten kinetics, THTR-1 is largely occupied at low luminal concentrations, so dose escalation buys you diminishing marginal absorption. Benfotiamine’s S-benzoyl ester lets it diffuse passively through enterocyte lipid bilayers, far less dependent on that route. Xie et al. (2014, PMID: 24399744) put numbers on it: roughly 1,147% relative plasma thiamine bioavailability, about 11-fold, and roughly 196% relative erythrocyte thiamine diphosphate (TDP), the biologically active form, alongside a markedly higher Cmax. That erythrocyte TDP figure is the one that matters, because it reflects intracellular TPP availability in circulating cells, not just plasma pharmacokinetics.

Stage 2: Intracellular Esterase Conversion and TPK-Mediated TPP Synthesis

Once absorbed, intracellular esterases cleave the S-benzoyl group and release free thiamine. Thiamine then gets phosphorylated to TPP, also called TDP, by thiamine pyrophosphokinase (TPK), which needs Mg²⁺ as an obligate cofactor. This is the step people forget. Without enough magnesium, even thiamine that arrived via benfotiamine’s superior passive diffusion converts less completely to functional TPP. Magnesium status, in other words, gates the whole activation. The 200mg magnesium bis-glycinate here (36mg elemental Mg²⁺) supports the TPK reaction and helps carry the substrate-to-active-form conversion through to completion.

Stage 3: TPP-Dependent Mitochondrial Enzyme Velocity Support

TPP is an essential cofactor for three enzymes that sit at genuine bottlenecks in energy metabolism: pyruvate dehydrogenase (PDH), which moves pyruvate to acetyl-CoA and into the Krebs cycle; α-ketoglutarate dehydrogenase (αKGDH), a rate-limiting Krebs step that generates NADH; and branched-chain α-keto acid dehydrogenase (BCKADH). When TPP runs short, their Vmax drops, and that throttles acetyl-CoA flux, NADH generation, and downstream ATP. If you’re optimizing for performance, adequate TPP for PDH and αKGDH is foundational in a way that upstream NAD+ and CoQ10 support simply don’t replace.*

Stage 4: Transketolase Activation and Upstream Flux Diversion

Transketolase is the TPP-dependent pentose phosphate pathway (PPP) enzyme that converts fructose-6-phosphate (F6P) and glyceraldehyde-3-phosphate (G3P) back into the PPP. When TPP is adequate, those glycolytic intermediates get channeled cleanly into the PPP. When TPP is limiting, F6P and G3P can pile up and feed the downstream damage pathways in the Brownlee framework: AGE formation via methylglyoxal and glyoxal, hexosamine activation, PKC-diacylglycerol activation, and polyol pathway throughput.

Hammes et al. (2003, Nature Medicine, PMID: 12592403) showed, in hyperglycemic and diabetic models, that benfotiamine raises transketolase activity (roughly threefold to fourfold in their cell models) and blocks three of those pathways (hexosamine, AGE formation, and DAG-PKC) plus NF-κB activation. Here’s the reasoning for why it may matter to someone metabolically healthy: F6P and G3P come out of normal carbohydrate metabolism at any blood glucose level, so the mechanism plausibly extends beyond elevated glucose. That extension is an inference from the biochemistry; it hasn’t been directly tested in normoglycemic humans.*

Du et al. (2008, Diabetologia, PMID: 18663426) took it further in a diabetic population, reporting that benfotiamine 600mg with alpha-lipoic acid 1200mg normalized elevated AGE formation, cut hexosamine-modified proteins by 40%, and restored prostacyclin synthase activity in nine type 1 diabetics, all of it independent of glycemic-control changes. Two caveats worth keeping straight: those findings are in diabetic subjects with elevated baseline AGE formation, and that proof-of-concept used a higher ALA dose than the 300mg in this formula. The 300mg ALA dose here matches the ISLAND vascular study instead.

Stage 5: ALPL-Independent P5P Cofactor Provision for Neurotransmitter Synthesis

Pyridoxal-5’-phosphate (P5P) is the active coenzyme for more than 100 enzyme systems, including DOPA decarboxylase (dopamine), tryptophan decarboxylase (serotonin), cystathionine beta-synthase, transaminases, and glycogen phosphorylase. Pyridoxine HCl has to be converted to active P5P first, and genetic variation at the ALPL locus tracks with differences in circulating PLP. The GWAS work (Olde Loohuis et al. 2018) identified ALPL variation (lead SNP rs1106357, MAF ~0.46) associated with plasma PLP at p = 7.89 × 10⁻¹⁰, with minor-allele homozygotes showing a 1.4× higher PLP:PL ratio in plasma and 1.6× in CSF. Some people with impaired conversion respond better to direct P5P than to pyridoxine. There’s also a safety angle: high-dose pyridoxine (>200mg/day) is associated with sensory neuropathy, and Vrolijk et al. (2017) found that pyridoxine, but not P5P, is neurotoxic to neuronal cells in vitro. The 30mg P5P here delivers the active coenzyme directly, at 30% of the US Upper Tolerable Limit.*

Stage 6: ALA Nrf2 Activation, AMPK-GLUT4 Translocation, and Antioxidant Defense

Alpha-lipoic acid pulls four jobs. First, antioxidant activity in both aqueous and lipid compartments through DHLA redox cycling, regenerating glutathione, ascorbate, and tocopherol. Second, Nrf2 activation via Keap1 cysteine modification, which upregulates phase II enzymes (γ-GCL, NQO1, HO-1, GSTs). Third, AMPK phosphorylation that drives insulin-independent GLUT4 translocation, supporting cellular glucose uptake with direct relevance to CGM-measurable postprandial variability. Fourth, cofactor function for PDH and αKGDH alongside TPP. On the clinical side, Sola et al. (2005, Circulation, PMID: 15655130) reported that the 300mg ALA arm, the exact dose in this formula, produced a 44% improvement in flow-mediated vasodilation in 58 metabolic-syndrome subjects over 4 weeks. That’s a trackable vascular endpoint, not a vague promise.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Biomarker-Linkable Outcomes for Quantified Self Protocol Integration

If you build measurable protocols, the point of this formula is that its mechanisms have biomarker correlates you can actually track. Keep in mind that the supporting trials ran in clinical populations, so for a metabolically healthy user these are reasonable experiments to run on yourself, not guaranteed outcomes.

CGM-Measurable Glucose Support

ALA’s AMPK activation and insulin-independent GLUT4 translocation support healthy glucose metabolism through a mechanism that’s distinct from, and additive to, dietary carbohydrate management.* For CGM users, that sets up a clean experiment: log baseline postprandial standard deviation and time-in-range before you start, then track the same meals afterward. This isn’t glucoregulation in the pharmaceutical sense. It supports healthy glucose metabolism through AMPK-mediated glucose disposal, and the CGM signature of that cellular uptake can be measurable.*

The practical read for CGM users: you’re watching whether your own standard-deviation and time-in-range trends shift on consistent meals, which is a way to see whether the cellular mechanism is engaged the way the pharmacokinetic studies suggest.

HRV and Recovery Support Through Mitochondrial ATP Flux

Mitochondrial ATP production efficiency is one input into HRV and recovery speed, sitting downstream of autonomic tone, which is itself regulated in part by cellular energy availability. TPP-dependent enzyme velocity at PDH and αKGDH governs how much acetyl-CoA and NADH reach oxidative phosphorylation.

Fraser et al. (2012, Diabetes Care, PMID: 22446172) reported that 300mg benfotiamine significantly increased whole-blood thiamine and thiamine diphosphate at p<0.001, which confirms the intracellular mechanism is engaged. Keep the context straight, though: that 24-month study did not find significant changes in nerve function or inflammatory markers, so it’s cited here for the biomarker and uptake finding plus long-term safety, nothing more. If you want direct confirmation for yourself, an erythrocyte TDP/TPP assay before and after is the cleanest experiment you can run. And since prefrontal neurons carry some of the highest mitochondrial density in the CNS, sustained cognitive performance often comes up in the same conversation.*

Healthy AGE-Related Pathways Through Transketolase Activation: The Decade-Horizon Consideration

AGE quantification keeps getting more accessible: serum AGE markers (carboxymethyllysine, methylglyoxal-modified proteins), skin autofluorescence, longevity panels. For early adopters building decade-horizon protocols, baseline AGE burden and its annual trajectory are the long-duration biomarker transketolase activation is designed to influence. This is a multi-year play, aimed at AGE accumulation from normal postprandial glycolytic flux at any glucose level.*

You won’t see this one on tomorrow’s dashboard. It shows up over years, in the AGE panel you re-run annually. Hammes et al. (2003) demonstrated substantial transketolase activation in hyperglycemic models, and Du et al. (2008) reported normalized elevated AGE formation with benfotiamine + ALA in diabetic subjects, independent of glycemic status. For metabolically healthy adults in their 30s and 40s, starting early is usually framed as the higher-value move, since supporting healthy AGE-related pathways early may be more efficient than trying to influence glycation that has already accumulated. That framing is mechanistic; long-term prevention outcomes in healthy adults haven’t been trial-confirmed.*

The satisfaction here is closer to the long-term investor’s than the athlete’s. Not the fast dopamine of a training PR, but the compound value of a position you hold consistently.

Stack Consolidation: Four Components to One CoA-Verified Formula

If you’re sourcing benfotiamine, P5P, chelated magnesium, and ALA separately, you’re probably paying $100+ a month across four supply chains and four lot-testing regimes, most with no CoA at all. This formula consolidates the whole combination at $40 to $45 monthly, GMP-certified, NSF/USP-approved third-party lot tested, with CoA documentation per lot and Fullscript availability. (Cost comparison based on average retail prices of standalone supplements as of [month/year]; pricing varies by brand and retailer.)

One bottle replaces four. One dosing schedule replaces four. The cost drops by more than half, and you keep the quality tier.

Active B-Vitamin Protocol Completion

If methylfolate and methylcobalamin are already in your protocol, this formula extends the logic you’ve been running. The THTR argument for benfotiamine over thiamine HCl mirrors the DHFR/MTHFR argument for methylfolate over folic acid, and the ALPL argument for P5P over pyridoxine HCl mirrors the MTR/MTRR argument for methylcobalamin over cyanocobalamin.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The Multi-Study Evidence Hierarchy Behind BioActive Vitamin B1™ 

The evidence stack runs deep, with the important caveat that the human trials were conducted in clinical populations: the Xie 2014 pharmacokinetic study (roughly 1,147% relative plasma thiamine bioavailability, 196% relative erythrocyte TDP versus thiamine HCl, in healthy volunteers); the BENDIP Phase III RCT in diabetic neuropathy (per-protocol between-group p=0.033, n=165, with the 600mg arm showing the greatest symptom improvement); the Hammes 2003 Nature Medicine paper in hyperglycemic models (transketolase activation, blockade of three glucose-damage pathways plus NF-κB); the Du 2008 Diabetologia proof-of-concept in type 1 diabetics (normalized elevated AGE formation independent of glycemic control); and ISLAND in metabolic syndrome (Sola 2005, Circulation: 300mg ALA produced a 44% improvement in flow-mediated vasodilation).

Xie et al. 2014, Pharmacokinetic Quantification (Lead Authority)

Journal of Clinical Pharmacology, PMID: 24399744. A pharmacokinetic study measuring plasma thiamine AUC and erythrocyte TDP after oral benfotiamine versus thiamine HCl in healthy volunteers. Results: ~1,147% relative plasma thiamine bioavailability, ~196% relative erythrocyte TDP, and a markedly higher Cmax. Erythrocyte TDP is the meaningful readout, because it reflects intracellular TPP in circulating cells.

Stracke et al. 2008 BENDIP Phase III, Dose Data

Experimental and Clinical Endocrinology & Diabetes, PMID: 18473286. A randomized, double-blind, placebo-controlled Phase III RCT in diabetic polyneuropathy, n=165 randomized, comparing 300mg versus 600mg benfotiamine versus placebo over 6 weeks. The Neuropathy Symptom Score differed significantly among the three groups in the per-protocol population (p=0.033), with the 600mg arm showing the greatest improvement. The intention-to-treat difference came in at p=0.055, and the Total Symptom Score showed no significant difference. Most commercial benfotiamine products sit at 150 to 300mg.

Hammes et al. 2003, Transketolase Mechanism, Nature Medicine

PMID: 12592403. A mechanistic investigation in diabetic and hyperglycemic retinal cell and animal models. Benfotiamine raised transketolase activity (roughly threefold to fourfold in the cell models) and blocked three downstream pathways of glucose toxicity (AGE formation, hexosamine flux, PKC-diacylglycerol activation) plus NF-κB activation. Relevance to normoglycemic humans is a mechanistic inference, not a tested finding.

Du et al. 2008, Benfotiamine + ALA, Diabetologia

PMID: 18663426. A proof-of-concept in 9 type 1 diabetic subjects, benfotiamine 600mg + ALA 1200mg over 4 weeks. Results: normalized elevated AGE formation, a 40% reduction in hexosamine-modified proteins, and restored prostacyclin synthase activity, all independent of glycemic-control changes. This study used a higher ALA dose than this formula’s 300mg.

Sola et al. 2005 ISLAND, ALA 300mg, Circulation

PMID: 15655130. 58 subjects with metabolic syndrome randomized to irbesartan 150mg/d, lipoic acid 300mg/d, both, or placebo over 4 weeks. The 300mg lipoic-acid arm showed a 44% improvement in flow-mediated vasodilation versus placebo (irbesartan alone 67%, combination 75%), with significant reductions in IL-6 and PAI-1.

Fraser et al. 2012, Whole-Blood TDP Confirmation, Diabetes Care

PMID: 22446172. A 24-month, double-blind, randomized, placebo-controlled study in type 1 diabetes (300mg/day benfotiamine). It found significant increases in whole-blood thiamine and thiamine diphosphate (both p<0.001 vs placebo), held over 24 months with a good safety profile. It found no significant differences in nerve function or inflammatory markers, so it’s cited here for the intracellular uptake biomarker and long-term safety.

ALPL GWAS, P5P Genetic Rationale

Olde Loohuis et al. (2018) identified ALPL locus variation (lead SNP rs1106357, MAF ~0.46) associated with plasma PLP at p = 7.89 × 10⁻¹⁰, with minor-allele homozygotes showing a 1.4× higher PLP:PL ratio in plasma and 1.6× in CSF, in healthy human subjects. This is the genetic-epidemiological basis for using the active P5P coenzyme directly instead of relying on pyridoxine-to-P5P conversion.

Manufacturing and Quality Credentials

GMP-certified per 21 CFR Part 111, FDA-registered facility. Third-party testing through NSF International or USP-approved laboratories. Heavy metals screened per California Prop 65. Complete Certificate of Analysis per production lot available. Fullscript practitioner dispensary availability means the product is carried on that platform.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

How BioActive Vitamin B1 Pairs a 600mg Benfotiamine Dose With a Complete TPP Cofactor Cascade

It’s one of the few formulas offering this exact four-component combination at these specifications in a single GMP-certified, CoA-transparent product:

The Biochemical Dependency Chain That Makes Each Component Purposeful

The design is a chain, not a pile. Benfotiamine delivers thiamine substrate via passive diffusion, magnesium lets TPK synthesize TPP, TPP activates PDH, αKGDH, and transketolase, transketolase helps divert F6P and G3P away from methylglyoxal and AGE-precursor formation, ALA supports antioxidant defense via Nrf2 induction and activates AMPK for glucose disposal, and P5P completes the neurotransmitter cofactor system the same energy infrastructure supports.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Protocol-Specific Questions

What is the THTR transporter Km and why does it create an absorption ceiling?

THTR-1 (SLC19A2) is a sodium-dependent, thiamine-specific carrier with a Km in the low micromolar range, roughly 2 to 2.5µM. THTR-2 (SLC19A3), on the luminal brush border, has been reported with a much lower, nanomolar-range Km, so it’s higher-affinity but still a finite carrier route. Near and above Km, extra substrate buys diminishing marginal absorption through THTR-1. Since lumen thiamine concentrations from even modest thiamine HCl doses can push past that Km, dose escalation ends up working on the flat part of the curve. Benfotiamine’s passive diffusion is less subject to that, which fits its markedly higher plasma thiamine AUC (Xie et al. 2014). The absorbed fraction of a large thiamine HCl dose is limited because the active-transport route is saturable.*

Does BioActive Vitamin B1™  interact with metformin or other metabolic medications?

Metformin’s AMPK activation is mechanistically compatible with ALA’s AMPK pathway; they run parallel, not in competition. Metformin also depletes B12 through interference with calcium-dependent ileal absorption of the B12-intrinsic factor complex (a well-documented interaction; see the NIH Office of Dietary Supplements Vitamin B12 fact sheet), a separate pathway, so if you manage B12 with methylcobalamin, keep that going, since this formula doesn’t contain B12. For levothyroxine, keep at least 2 hours of separation. For statins, no direct interaction identified. Check with your prescribing physician for a personalized assessment.*

How long until biomarker changes are measurable on CGM or HRV?

Whole-blood and erythrocyte TDP increases usually show within 2 to 4 weeks. CGM changes may appear within 4 to 8 weeks, depending on dietary consistency and CGM sensitivity. HRV changes often take 6 to 12 weeks. FMD was measured at 4 weeks in ISLAND. AGE-specific biomarkers reflect decade-horizon changes.*

What’s the evidence for P5P over pyridoxine without a confirmed ALPL variant?

Two reasons. Prevalence: the ALPL variant tied to PLP status is common (MAF ~0.46), so a lot of people carry it, and P5P sidesteps the conversion question regardless of genotype. Safety: high-dose pyridoxine is associated with sensory neuropathy, and Vrolijk et al. (2017) found pyridoxine, not P5P, is neurotoxic to neuronal cells in vitro. The 30mg dose here is 30% of the US Upper Tolerable Limit.*

I already run an extensive protocol. What’s my actual risk?

Financially, a 60-day money-back guarantee caps it. On the protocol side, the risk is low: four ingredients with clean safety profiles and no known interactions with NAD+ precursors, resveratrol, or rapamycin. The sharper framing is opportunity cost. If you’ve already covered NAD+ signaling, methylation, and mTOR, the THTR saturation gap and the ALPL conversion question are among the more likely bioavailability holes left. Sixty days of erythrocyte TPP testing, before and after, is the definitive personal experiment.*

How does the evidence quality here compare to other longevity interventions?

It compares well on venue and design: a quantitative PK comparison (Xie 2014), a 165-patient RCT (BENDIP), a Nature Medicine mechanism study (Hammes 2003), a Diabetologia study (Du 2008), and a Circulation trial (ISLAND). Be honest about the limits, though. Several of these trials ran in diabetic or metabolic-syndrome populations rather than metabolically healthy adults, and some primary endpoints (Gibson 2020’s ADAS-Cog, Fraser 2012’s nerve function) didn’t reach significance. That’s context worth weighing.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BioActive Vitamin B1: The Benfotiamine Complete Cofactor System That Helps Address the Thiamine and B6 Gap in Your Active-Form Protocol

BioActive Vitamin B1™  is a benfotiamine complete cofactor system engineered for metabolic performance support: 600mg fat-soluble benfotiamine with markedly higher plasma thiamine delivery than thiamine HCl (Xie et al. 2014), chelated magnesium for thiamine pyrophosphokinase activation, active P5P that helps sidestep ALPL-associated conversion variability, and pharmaceutical-grade ALA at the ISLAND-validated 300mg dose.*

The THTR saturation ceiling is real and pharmacokinetically quantified. The ALPL variant is common and documented at genome-wide significance. AGE precursors form from normal postprandial glycolytic flux at any glucose level, which is why this is positioned as everyday healthy-aging support rather than a disease intervention. Transketolase activation via benfotiamine reaches an upstream mechanism your NAD+ and mTOR protocols don’t.

When this protocol addition may be a fit: - ✓ Quantified self practitioners with CGM interested in ALA’s AMPK-GLUT4 mechanism for glucose-disposal support - ✓ Adults already using methylfolate and methylcobalamin who see the same ALPL and THTR arguments applying to B6 and thiamine - ✓ Longevity-focused individuals seeking healthy AGE-related pathway support through transketolase activation - ✓ Supplement stackers sourcing benfotiamine, P5P, chelated Mg, and ALA separately at $100+/month - ✓ HRV and recovery trackers interested in mitochondrial ATP flux support through TPP-dependent enzyme velocity - ✓ Research-literate individuals who want the dose and combination the Xie 2014 and Hammes 2003 papers support - ✓ Practitioners who need a single Fullscript-available product with evidence documentation and CoA transparency

When this isn’t the priority: - ○ Primary stack gap is NAD+ signaling (NMN/NR more appropriate, different mechanism) - ○ mTOR modulation is the primary lever (different pathway) - ○ Severe chronic kidney disease present (consult a nephrologist before cofactor supplementation)

Not evaluated for use during pregnancy or nursing; if you are pregnant, nursing, taking medication, or managing a medical condition, consult your healthcare provider before use.

Learn More About BioActive Vitamin B1™  →

GMP-certified. NSF/USP third-party lot tested. CoA documentation available. Fullscript practitioner dispensary available.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BioActive Vitamin B1: Full Pharmacological Documentation

Benfotiamine (S-Benzoylthiamine-O-Monophosphate), 600mg

Molecular weight 466.5 g/mol. Intracellular metabolism runs esterase cleavage of the S-benzoyl group, then free thiamine, then TMP, then TPP via TPK (Mg²⁺-dependent). TPP is an obligate cofactor for PDH, αKGDH, BCKADH, and transketolase. The 600mg dose matches the highest BENDIP arm (Stracke et al. 2008), the Gibson 2020 cognitive RCT dose, and the Du 2008 study dose. Gibson et al. (2020, PMID: 33074237), in a mild cognitive impairment / Alzheimer’s population, reported a 161-fold mean increase in blood thiamine at 600mg/day and a 77% lower worsening on the CDR (p=0.034, a secondary outcome; the primary ADAS-Cog outcome did not reach significance, p=0.125). Phase I work tested up to 1200mg with dose-proportional pharmacokinetics. It carries an established safety profile with wide margins over clinical doses.

Pyridoxal-5’-Phosphate (P5P), 30mg

USP grade, ≥98.5% purity by HPLC. The active coenzyme form of B6, used directly by DOPA decarboxylase, aromatic L-amino acid decarboxylase, cystathionine beta-synthase, aminotransferases, and glycogen phosphorylase. ALPL variation is associated with plasma PLP (Olde Loohuis et al. 2018; lead SNP rs1106357, MAF ~0.46; p = 7.89 × 10⁻¹⁰). Safety: 30mg is 30% of the US Tolerable Upper Limit. No neurotoxicity pathway has been identified for P5P at doses studied, in contrast to pyridoxine above 200mg/day (Vrolijk et al. 2017, PMID: 28716455).

Magnesium Bis-glycinate, 200mg (36mg Elemental Magnesium)

A chelated form that supports absorption across the GI pH range. The 36mg elemental dose is calibrated for TPK cofactor support, not therapeutic magnesium supplementation (typically 200 to 400mg elemental). TPK needs Mg²⁺ at its catalytic center for the ATP-dependent phosphoryl transfer to thiamine.

Alpha-Lipoic Acid (Racemic, R:S 50:50), 300mg

Pharmaceutical-grade racemic ALA at ≥99% purity by HPLC. The major clinical trials (ISLAND, SYDNEY 2, NATHAN 1, Du 2008) used racemic mixtures. Mechanisms: radical scavenging; DHLA-mediated regeneration of glutathione, ascorbate, and tocopherol; Nrf2 activation via Keap1 modification; AMPK activation driving GLUT4 translocation; and lipoamide cofactor function in PDH and αKGDH. Fogacci et al. (2020) reported, in a systematic review and meta-analysis of ALA supplementation, no increased adverse-event risk versus placebo across dose ranges.

Drug and Supplement Interaction Guidance

Levothyroxine: 2-hour separation. Statins: no direct pharmacokinetic interaction. Metformin: parallel AMPK mechanisms are compatible, and metformin’s B12 depletion is unrelated to thiamine and B6 pathways. NMN/NR: no interaction. Methylfolate + methylcobalamin: no interaction, and P5P’s role in cystathionine beta-synthase complements their role in remethylation. High-dose standalone magnesium: no interaction, since the 36mg elemental Mg here is cofactor-support dosing.

Not evaluated for use during pregnancy or nursing; consult your healthcare provider before use if you are pregnant, nursing, taking medication, or managing a medical condition.

Extended FAQ, Technical Depth

R-ALA versus racemic ALA for this formulation?

R-ALA has higher binding affinity and may produce greater mitochondrial uptake per mg, but the major clinical trials (ISLAND, SYDNEY 2, NATHAN 1, Du 2008) all used racemic mixtures, R-ALA is less stable, and it costs 3 to 5× more per gram. For a formula optimized for efficacy-per-cost at validated doses, racemic at ≥99% purity is the evidence-aligned choice.

How does this fit a protocol that already includes CoQ10?

CoQ10 is an electron carrier in the electron transport chain, downstream of the Krebs cycle. Benfotiamine’s TPP-dependent enzyme support works upstream, at substrate entry into the cycle. They’re complementary: CoQ10 optimizes turbine efficiency, benfotiamine supports fuel delivery to the turbine.

Any evidence for benfotiamine on homocysteine?

Homocysteine clears through two routes: remethylation (MTHFR/MTR, needing methylfolate and methylcobalamin) and transsulfuration (cystathionine beta-synthase, needing P5P). This formula’s P5P supports CBS activity, the first committed transsulfuration step. There’s no direct evidence for benfotiamine itself on homocysteine; the P5P component is the relevant mechanism.

What erythrocyte biomarker panel confirms mechanism engagement?

An erythrocyte TDP/TPP assay, available through specialty labs, directly measures intracellular TPP availability, the biomarker Fraser et al. (2012) reported increases with benfotiamine. Baseline plus a 4 to 6-week retest gives you direct confirmation. Plasma PLP can confirm B6 status, and serum AGE markers (CML, pentosidine) cover decade-horizon tracking.

If I already take 600mg benfotiamine, what does this add?

Four things at the margin: magnesium bis-glycinate for TPK cofactor support; active P5P to address the conversion question if you’re running pyridoxine HCl elsewhere; 300mg pharmaceutical-grade ALA (the ISLAND-validated vascular endpoint); and single-facility GMP manufacturing with CoA cohesion. Weigh your current stack against those specific additions.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The THTR Saturation Ceiling Is Real. The ALPL Variant Is Common. AGE Formation From Normal Glycolytic Flux Is Cumulative.

The Xie 2014 study is PMID: 24399744. The BENDIP Phase III is PMID: 18473286. The Hammes 2003 Nature Medicine study is PMID: 12592403. The Du 2008 Diabetologia study is PMID: 18663426. The ISLAND study is PMID: 15655130. Verify every number independently.

Learn More About BioActive Vitamin B1™  →

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Scientific References & Citations

Du, X., Edelstein, D., & Brownlee, M. (2008). Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia, 51(10), 1930–1932. https://doi.org/10.1007/s00125-008-1100-2 (PMID: 18663426)

Fogacci, F., Rizzo, M., Krogager, C., et al. (2020). Safety evaluation of α-lipoic acid supplementation: A systematic review and meta-analysis of randomized placebo-controlled clinical studies. Antioxidants, 9(10), 1011. https://doi.org/10.3390/antiox9101011 (PMID: 33086555)

Fraser, D. A., Diep, L. M., Hovden, I. A., Nilsen, K. B., Sveen, K. A., Seljeflot, I., & Hanssen, K. F. (2012). The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: A 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care, 35(5), 1095–1097. https://doi.org/10.2337/dc11-1895 (PMID: 22446172)

Gibson, G. E., Luchsinger, J. A., Cirio, R., Chen, H., Franchino-Elder, J., Hirsch, J. A., Bettendorff, L., Chen, Z., Flowers, S. A., Gerber, L. M., Grandville, T., Schupf, N., Xu, H., Stern, Y., Habeck, C., Jordan, B., & Fonzetti, P. (2020). Benfotiamine and cognitive decline in Alzheimer’s disease: Results of a randomized placebo-controlled Phase IIa clinical trial. Journal of Alzheimer’s Disease, 78(3), 989–1010. https://doi.org/10.3233/JAD-200896 (PMID: 33074237)

Hammes, H. P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., Neumaier, M., Bergfeld, R., Giardino, I., & Brownlee, M. (2003). Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine, 9(3), 294–299. https://doi.org/10.1038/nm834 (PMID: 12592403)

Olde Loohuis, L. M., Albersen, M., de Jong, S., Wu, T., Luykx, J. J., Jans, J. J. M., Verhoeven-Duif, N. M., & Ophoff, R. A. (2018). The alkaline phosphatase (ALPL) locus is associated with B6 vitamer levels in CSF and plasma. Genes, 10(1), 8. https://doi.org/10.3390/genes10010008 (PMID: 30583557)

Sola, S., Mir, M. Q. S., Cheema, F. A., Khan-Merchant, N., Menon, R. G., Parthasarathy, S., & Khan, B. V. (2005). Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation, 111(3), 343–348. https://doi.org/10.1161/01.CIR.0000153272.48711.B9 (PMID: 15655130)

Stracke, H., Gaus, W., Achenbach, U., Federlin, K., & Bretzel, R. G. (2008). Benfotiamine in diabetic polyneuropathy (BENDIP): Results of a randomised, double blind, placebo-controlled clinical study. Experimental and Clinical Endocrinology & Diabetes, 116(10), 600–605. https://doi.org/10.1055/s-2008-1065351 (PMID: 18473286)

Vrolijk, M. F., Opperhuizen, A., Jansen, E. H. J. M., Hageman, G. J., Bast, A., & Haenen, G. R. M. M. (2017). The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicology in Vitro, 44, 206–212. https://doi.org/10.1016/j.tiv.2017.07.009 (PMID: 28716455)

Xie, F., Cheng, Z., Li, S., Liu, X., Guo, X., Yu, P., & Gu, Z. (2014). Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. Journal of Clinical Pharmacology, 54(6), 688–695. https://doi.org/10.1002/jcph.261 (PMID: 24399744)

Regulatory: cGMP per 21 CFR Part 111; NSF International / USP-approved third-party lot testing; Prop 65 heavy metals screening; Certificate of Analysis per production lot.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before beginning any supplement regimen.